Rein Therapeutics, Inc. Common Stock RNTX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Cost of Goods Sold by Product | ||||||
| License And Maintenance | $9K+12.5% | $8K-55.6% | $18K— | $0-100% | $9K+12.5% | |
| License | $0— | $0-100% | $25K— | $0— | $0— | |
| Research And Development Expense by Product | ||||||
| Clinical Operation Activities | $1.96M+89.3% | $1.04M+150% | $414K-80.9% | $2.16M+221% | $673K-30.3% | |
| CMC Activities | $520K-8.9% | $571K+110% | $272K-67.5% | $836K+49.3% | $560K+226% | |
| Employee Related Expenses | $500K+0.6% | $497K+4.0% | $478K-8.3% | $521K-16.2% | $622K+2.5% | |
| Facilities And Other Expenses | $25K+92.3% | $13K-45.8% | $24K+14.3% | $21K+31.3% | $16K+23.1% | |
| Preclinical Study Costs | $0— | —— | $294K+10.1% | $267K-52.0% | $556K+16.8% | |
| Professional Fees For Services | $0— | $0-100% | $6K-71.4% | $21K+23.5% | $17K— | |
| General And Administrative Expense by Product | ||||||
| Employee Related Expenses | $859K-8.5% | $939K+1.3% | $927K-0.9% | $935K-1.3% | $947K+59.2% | |
| Facilities And Other Expenses | $508K+20.7% | $421K-9.3% | $464K-23.7% | $608K+29.4% | $470K+4.4% | |
| Professional Fees For Services | $790K+32.1% | $598K-75.3% | $2.42M+134% | $1.04M-9.0% | $1.14M-20.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Rein Therapeutics, Inc. Common Stock break its business down?
- Rein Therapeutics, Inc. Common Stock (RNTX) reports cost of goods sold by product across 2 parts — License And Maintenance and License. Each is extracted from the segment footnotes and tracked over time.
- Where does Rein Therapeutics, Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Rein Therapeutics, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.